Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones / How Startups Use the Rolling Close to Raise Capital in Weeks
Transcript
- Lucas: So it's late May 2026, and if you've watched the ARK ETFs this week, you noticed something. The Genomic Revolution fund, ARKG, jumped over nine percent in five days. ARKK itself up two and a half. That kind of sector momentum doesn't just move public market money—it reshapes where early-stage VCs are fishing. Luna: Right, because when a thematic ETF catches fire, suddenly every partner wants to say they're 'looking at genomics.' And that creates a window for startups. Lucas: Exactly. And one of the cleverest ways founders are exploiting that window right now is something called the rolling close. It's not new—Y Combinator SAFEs have had rolling caps for years—but it's becoming the dominant structure for a lot of Series A rounds, especially in fast-moving sectors like biotech and AI. Luna: Let's back up. What is a rolling close, exactly, for someone who's never raised before? Lucas: Simple version: instead of raising your entire round at one moment—sign one big term sheet, close all at once—you open a round and let investors commit over a period of weeks or months. Each investor signs their own subscription agreement, and the round 'closes' multiple times as new money comes in. Luna: So it's like a rolling admissions process for capital. You don't wait for the lead to finish due diligence on everyone. You take money as it shows up. Lucas: Exactly. And the beauty is momentum. If you've got a hot sector tailwind—say, AI drug discovery, which is where a lot of that ARKG money is flowing—you can announce your first close with a lead investor, then use that as social proof to bring in a second tranche at a slightly higher valuation. Luna: And that's the piece that trips founders up. Can you really raise at different prices within the same round? Lucas: You can, if you structure it correctly. Typically you set a valuation cap or a discount for early investors, then a higher price for later ones. The key is that everyone ends up with the same security—usually a SAFE or a priced round with a single series of shares—so there's no preference stack nightmare. Luna: I've seen some VCs push back on this. They say it creates adverse selection—the best investors wait till the last close, and you end up with a bunch of smaller checks from less strategic partners. Lucas: That's a real risk. If you're not careful, your first close ends up being your weakest investors, and the ones you really want—the Sequoias, the a16z—hold out till the end, or never come in because they see a messy cap table. Luna: So how do you avoid that? How do you keep the round strategic? Lucas: You anchor with a strong lead at the first close. Even if that lead writes a smaller check initially, you want someone with brand credibility. That way when you go to later investors, you say, 'Sequoia's already in at this valuation,' and suddenly your rolling close has a gravity well. Luna: And what about the legal mechanics? I assume you can't just collect checks and figure out the paperwork later. Lucas: No, you need a good securities lawyer. Because each close is a separate issuance of securities, you have to file a Form D with the SEC each time. But for most early-stage rounds under the 506 exemption, that's just a notification. The real work is in the subscription agreement—making sure each investor signs the same governing documents, typically a SAFE or a convertible note, with the same terms except price. Luna: There's also the optics issue. If your rolling close drags on for six months, it signals that the market isn't excited. You want it to feel like a sprint, not a marathon. Lucas: Exactly. The best rolling closes I've seen happen within four to six weeks. You open the round, you've got two or three anchor investors lined up before you even announce it, then you do a concentrated push to fill the round. If it goes past eight weeks, investors start wondering why nobody else has committed. Luna: And that's where the sector momentum matters. If you're in genomics right now, with ARKG up nine percent in a week, you can ride that wave. Investors are already thinking about the space—you're just giving them a vehicle. Lucas: Which is exactly what a lot of biotech founders are doing. I know of a startup in the AI drug discovery space that raised a rolling Series A in March. They started with a $5 million first close at a $20 million cap, then four weeks later closed another $3 million at a $25 million cap. Total raise $8 million, and the second tranche came from a top-tier crossover fund. Luna: That's a great example of the valuation step-up working in practice. But what about the downside? If the market turns, you could be stuck with a half-filled round at a valuation that's no longer defensible. Lucas: That's the real danger. If you price your first close too high, and then the sector cools—say ARKG drops twenty percent—you're trying to raise the rest of the round at a valuation that looks silly. Some founders end up having to do a down round for the second close, which is a nightmare for early investors. Luna: So you need to be conservative on the first close valuation, even if you think you could get more. Leave room for the step-up. Lucas: Exactly. I've seen founders push for a $30 million cap on the first close when the comps suggest $20 million. They get the money, but then they can't attract a second close at $35 million because the market says no. So they sit there with a half-raised round and a lot of explaining to do. Luna: It's like a game of chicken with the market. You have to guess where the momentum will be in six weeks. Lucas: But there's another angle here that I think is underappreciated. The rolling close lets you test the market's appetite for your story without committing to a full round. You put out a small first close, see who bites, and then adjust your narrative for the second close based on feedback. Luna: That's smart. It's basically a lean startup approach to fundraising—iterate on your pitch in real time. Lucas: Yeah, and I've seen founders use the data from the first close to refine their positioning. If your first close comes mostly from health-tech VCs but not from pure biotech funds, you know you need to emphasize the platform play more. You can rewrite your pitch deck for the second close. Luna: That's a huge advantage over the traditional one-and-done round where you get one shot to tell your story. Lucas: Right. And the other advantage is speed. A rolling close can happen in weeks, whereas a traditional Series A with a single lead investor can take three to six months of due diligence, negotiations, and board approvals. In a hot sector, that speed is a competitive moat. Luna: Especially if you're competing for talent or customers against other well-funded startups. The faster you have cash in the bank, the faster you can hire. Lucas: Exactly. So if you're a founder raising in Q2 2026, especially in a sector with strong momentum like genomics or AI, the rolling close is a tool you should have in your kit. But use it wisely—anchor with a strong lead, keep the timeline tight, and leave room for a valuation step-up. Luna: And if you're listening and you've used a rolling close, we'd love to hear how it went. What worked, what didn't. Lucas: Yeah, drop us a line. For now, I'm Lucas. Luna: And I'm Luna. Thanks for listening.